NCT01420042 - Safety Study of NNZ-2566 in Healthy Subjects, Following Oral Administration | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

September 30, 2012

Conditions

Brain Injuries, Traumatic

Interventions

DRUG

NNZ-2566

Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.

DRUG

Placebo

Lemon flavoured cordial and Water for Injection

Trial Locations (1)

Unknown

Nucleus Network, Melbourne